Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxyphenonium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 known ✓ | P11229 | 4/20 | 1.00 |
| ▸ | CHRM3 known ✓ | P20309 | 2/20 | 0.62 |
| ▸ | CHRM2 | P08172 | 4/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 3/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.64 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxyphenonium SCHEMBL250614 | 1.00 | CHRM2 (1.00) | CHRM2CHRM1KCNH2SLC6A3LMNA | |
| Oxyphenonium SCHEMBL248890 | 0.99 | CHRM2 (0.98) | CHRM2CHRM1KCNH2SLC6A3LMNA | |
| Oxyphenonium SCHEMBL2030870 | 0.99 | CHRM2 (0.98) | CHRM2CHRM1KCNH2SLC6A3LMNA | |
| SCHEMBL23489737 | 0.91 | CHRM2 (0.84) | CHRM2CHRM1KCNH2SLC6A3LMNA | |
| Hydrochloric Acid SCHEMBL29894890 | 0.89 | CHRM2 (0.81) | CHRM2CHRM1KCNH2SLC6A3LMNA | |
| SCHEMBL2999990 | 0.89 | CHRM2 (0.81) | CHRM2CHRM1KCNH2SLC6A3LMNA | |
| SCHEMBL13266147 | 0.85 | POLB (0.76) | CHRM2CHRM1KCNH2SLC6A3LMNA | |
| SCHEMBL16887879 | 0.83 | CHRM2 (0.71) | CHRM2CHRM1KCNH2SLC6A3LMNA | |
| SCHEMBL13574067 | 0.82 | CHRM2 (0.70) | CHRM2CHRM1KCNH2SLC6A3LMNA | |
| SCHEMBL290176 | 0.82 | CHRM2 (0.70) | CHRM2CHRM1KCNH2SLC6A3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1606 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026100654-A1 | NUCLEIC ACID INTRODUCTION AID, NUCLEIC ACID INTRODUCTION AGENT, AND NUCLEIC ACID INTRODUCTION METHOD | 株式会社インファーマシア | 2026-05-15 | — | — | WO | claimed |
| EP-4630413-A1 | FLAVANONE COMPOUNDS AND THEIR USE AS FLAVOR MODIFIERS | Firmenich Incorporated (US) | 2025-10-15 | — | — | EP | claimed |
| US-20250302814-A1 | METHODS AND COMPOSITIONS FOR TREATING SLEEP APNEA | APNIMED, INC. (DELAWARE) | 2025-10-02 | — | — | US | claimed |
| US-20250271426-A1 | REDUCTION OF BITTER TASTE OF ACTIVE PHARMACEUTICAL INGREDIENTS AND RELATED ASSAYS AND SCREENING METHODS | FIRMENICH INCORPORATED (US) | 2025-08-28 | — | — | US | claimed |
| US-20250241933-A1 | METHODS OF TREATING SLEEP APNEA WITH A COMBINATION OF A CANNABINOID AND A CARBONIC ANHYDRASE INHIBITOR | APNIMED, INC. (DELAWARE) | 2025-07-31 | — | — | US | claimed |
| EP-4543431-A1 | METHODS OF TREATING SLEEP APNEA WITH A COMBINATION OF A CANNABINOID AND A CARBONIC ANHYDRASE INHIBITOR | APNIMED, INC. (DELAWARE) (US) | 2025-04-30 | — | — | EP | claimed |
| US-20250090545-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF PERIPHERAL NEUROPATHIES | UNIV MANITOBA (CA) | 2025-03-20 | — | — | US | claimed |
| EP-4493928-A1 | REDUCTION OF BITTER TASTE OF ACTIVE PHARMACEUTICAL INGREDIENTS AND RELATED ASSAYS AND SCREENING METHODS | Firmenich Incorporated (US) | 2025-01-22 | — | — | EP | claimed |
| US-20240358709-A1 | METHODS AND COMPOSITIONS FOR TREATING SLEEP APNEA | APNIMED, INC. (DELAWARE) | 2024-10-31 | — | — | US | claimed |
| EP-4448506-A1 | FLAVANONE COMPOUNDS AND THEIR USE AS FLAVOR MODIFIERS | Firmenich Incorporated (US) | 2024-10-23 | — | — | EP | claimed |
| WO-1992021350-A1 | COMBINATION OF NSAIDS AND PROSTAGLANDINS AND USES THEREFOR | SEPRACOR, INC. (US) | 1992-12-10 | — | — | WO | claimed |
| EP-0126684-B1 | DRUG DELIVERY SYSTEM UTILIZING THERMOSETTING GELS | MERCK & CO. INC. (US) | 1991-08-28 | — | — | EP | claimed |
| EP-0427725-A4 | WATER-SOLUBLE COMPLEXES OF PHARMACEUTICALS | — | 1991-08-21 | — | — | EP | claimed |
| EP-0427725-A1 | WATER-SOLUBLE COMPLEXES OF PHARMACEUTICALS | GAF CHEMICALS CORPORATION (US) | 1991-05-22 | — | — | EP | claimed |
| EP-0354502-A1 | Indomethacin injections and their production method | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1990-02-14 | — | — | EP | claimed |
| WO-1989007941-A1 | WATER-SOLUBLE COMPLEXES OF PHARMACEUTICALS | GAF CHEMICALS CORPORATION (US) | 1989-09-08 | — | — | WO | claimed |
| EP-0167958-A2 | Oral solid pharmaceutical form with sequential action for the administering of drugs with ulcerogenic side effect | LABORATORIO ITALIANO BIOCHIMICO FARMACEUTICO LISAPHARMA S.P.A. (IT) | 1986-01-15 | — | — | EP | claimed |
| EP-0165696-A2 | Improved transdermal dosage form | AMERICAN HOME PRODUCTS CORPORATION (US) | 1985-12-27 | — | — | EP | claimed |
| EP-0126684-A2 | Drug delivery system utilizing thermosetting gels | MERCK & CO. INC. (US) | 1984-11-28 | — | — | EP | claimed |
| US-4474751-A | SUSTAINED RELEASE USING AN ALKYLENEDIAMINE-MODIFIED ETHYLENE OXIDE-PROPYLENE OXIDE COPOLYMER | MERCK & CO., INC. (US) | 1984-10-02 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250090545-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF PERIPHERAL NEUROPATHIES | PMP22, CHRNA7, CHRNB3 | CHRM1 35/4885CHRM3 16/4885CHRM2 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.